FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

FT522 drug product is administered as an intravenous infusion on Days 1, 4 and 8 of a treatment cycle.

Rituximab will be administered as an IV infusion on Day -4 of the treatment cycle.

Cyclophosphamide will be administered as an IV infusion at a dose of 500 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.

Fludarabine will be administered as an IV infusion at a dose of 30 mg/m\^2 on Day -5, Day -4, and Day -3 of the treatment cycle.

Bendamustine will be administered as an IV infusion at a dose of 90 mg/m\^2 on Day -5 and Day -4 of the treatment cycle. Bendamustine may be administered as an alternative to cyclophosphamide/fludarabine.